These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18501425)

  • 1. Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia.
    Lu H; Lu SF; Shen WY; Hong M; Zhang JF; Wang LX; Yang H; Li JY
    Leuk Res; 2008 Nov; 32(11):1776-9. PubMed ID: 18501425
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
    Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
    Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute myelogenous leukaemia.
    Löwenberg B
    J Intern Med Suppl; 1997; 740():17-22. PubMed ID: 9350177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
    Xue SL; Wu DP; Sun AN; Tang XW
    Am J Hematol; 2008 Feb; 83(2):167-70. PubMed ID: 17874449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
    Nakamura Y; Arai Y; Gunji H; Arai H; Nakamura F; Handa T; Tadokoro J; Maki K; Saito K; Mitani K
    Rinsho Ketsueki; 2002 Oct; 43(10):960-2. PubMed ID: 12462034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
    Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
    Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative evaluation of CHAG and CAG priming regimen for treatment of refractory and relapsed acute myeloid leukemia].
    Chen L; Wei XD; Yin QS
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):484-6. PubMed ID: 22967387
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of acute myelogenous leukemia].
    Ono R
    Nihon Naika Gakkai Zasshi; 1992 Jul; 81(7):1040-5. PubMed ID: 1383364
    [No Abstract]   [Full Text] [Related]  

  • 10. [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
    Yamamoto K; Nagata K; Morita Y; Hamaguchi H
    Rinsho Ketsueki; 2002 Jun; 43(6):488-92. PubMed ID: 12134707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IL-2 post-autologous transplant of hematopoietic stem cells].
    Rayon C
    Sangre (Barc); 1997 Apr; 42 Suppl 1():37. PubMed ID: 9381299
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
    Zu Y; Zhang Y; Zhou J; Zhao H; Gui R; Li Z; Li M; Wei X; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):334-6. PubMed ID: 27093999
    [No Abstract]   [Full Text] [Related]  

  • 16. Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
    Büchner T; Berdel WE; Hiddemann W
    N Engl J Med; 2004 May; 350(21):2215-6. PubMed ID: 15152074
    [No Abstract]   [Full Text] [Related]  

  • 17. [Curative effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome].
    Zhu Y; He Y; Chen S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):370-3. PubMed ID: 20448361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia].
    Shen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):1-2. PubMed ID: 21429391
    [No Abstract]   [Full Text] [Related]  

  • 19. Salvaging AML with CLAG: novel option, or more of the same?
    Wei A; Teh TC
    Leuk Res; 2011 Mar; 35(3):297-8. PubMed ID: 21074270
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical outcome of CAG regimen in 26 children with aucte myeloid leukemia].
    Chen X; Ruan M; Liu F; Liu TF; Chen XJ; Guo Y; Zhang L; Yang WY; Chang LX; Zhao BB; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):594-596. PubMed ID: 32397024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.